Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA – Get Free Report) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.10 and traded as high as $2.67. Sonoma Pharmaceuticals shares last traded at $2.58, with a volume of 35,479 shares trading hands.
Sonoma Pharmaceuticals Price Performance
The company has a market capitalization of $3.51 million, a PE ratio of -0.53 and a beta of 1.41. The company’s fifty day moving average is $2.74 and its 200-day moving average is $2.12.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC purchased a new stake in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA – Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned about 1.08% of Sonoma Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 1.95% of the company’s stock.
Sonoma Pharmaceuticals Company Profile
Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.
Featured Stories
- Five stocks we like better than Sonoma Pharmaceuticals
- Best Stocks Under $5.00
- 4 Social Media Stocks Set to Gain as TikTok Ban Looms
- Industrial Products Stocks Investing
- How Do Stock Buybacks Affect Shareholders?
- NYSE Stocks Give Investors a Variety of Quality Options
- JPMorgan Chase & Co. Stock Can Hit $300 This Year
Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
